Navigation Links
ERT Reports Fourth Quarter and Full Year 2010 Operating Results on March 1, 2011
Date:2/9/2011

PHILADELPHIA, Feb. 9, 2011 /PRNewswire/ -- ERT (Nasdaq: ERES) announced today that it will release its operating results for fourth quarter and full year 2010 Tuesday, March 1, after the market closes. After the release, the Company will host a conference call at 5:00 PM ET that day.

For the conference call, interested participants should dial 1-800-860-2442 when calling within the United States or 1-412-858-4600 when calling internationally. There will be a playback available as well. To listen to the playback, please call 1-877-344-7529 when calling within the United States or 1-412-317-0088 when calling internationally.  Conference code for playback is 448386.

This call is being webcast by MultiVu and can be accessed at ERT's website at www.ert.com. The webcast may also be accessed via the direct link at http://www.videonewswire.com/event.asp?id=76717.   The webcast can be accessed for up to one year on either site.  

ERT (www.ert.com) is a global technology-driven provider of clinical services and customizable medical devices to biopharmaceutical and healthcare organizations.  It is the market leader for centralized cardiac safety and respiratory efficacy services in drug development and also collects, analyzes and distributes electronic Patient Reported Outcomes (ePRO) in multiple modalities across all phases of clinical research.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties, which could cause actual results to differ materially from those expressed or implied from such statements. These risks and uncertainties include, without limitation, the Company's ability to obtain new contracts, variability in size, scope, and duration of projects, integration of acquisitions, competitive factors, technological development, market demand, and other factors described in the Company's filings with the Securities and Exchange Commission.  The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.Media Contact:Keith Schneck, CFOTel: 215-972-0420kschneck@ert.com
'/>"/>

SOURCE ERT
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
2. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
3. Par Pharmaceutical Reports Second Quarter 2008 Results
4. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
5. Pharmos Corporation Reports 2008 Second Quarter Results
6. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
7. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
8. BMP Sunstone Reports Second Quarter 2008 Financial Results
9. ULURU Inc. Reports Second Quarter 2008 Financial Results
10. Immtech Reports Fiscal First Quarter 2009 Results
11. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... PARK, Calif., March 23, 2017  BioPharmX Corporation ... products for the dermatology market, today reported financial ... 31, 2017, and will provide an update on ... the year. "We are pleased to ... year for BioPharmX," said President Anja Krammer. "We ...
(Date:3/23/2017)... 2017  Agriculture technology company Cool Planet has closed ... conversion to commercialize its Cool Terra and Cool Fauna ... products that are simultaneously profitable as well as sustainable ... 18 months. This latest round of funding was led ... The company,s primary product, Cool Terra, can ...
(Date:3/22/2017)... , March 22, 2017  Ascendis Pharma A/S ... innovative TransCon technology to address significant unmet medical ... for the full year ended December 31, 2016. ... for our company as we broadened our pipeline ... integrated rare disease company with an initial focus ...
(Date:3/22/2017)... , March 22, 2017 ... fragmented, states a research report by Transparency Market Research ... Inc., Amgen Inc., and AbbVie Inc., accounted for a ... The prominent players in this market are focusing aggressively ... product portfolio, which is likely to lead to market ...
Breaking Biology Technology:
(Date:3/20/2017)... Pa. , March 20, 2017 PMD ... 2.0 personal spirometer and Wellness Management System (WMS), a ... Founded in 2010, PMD Healthcare is a Medical ... with a mission dedicated to creating innovative solutions that ... life. With that intent focus, PMD developed the first ...
(Date:3/13/2017)... HAMBURG, Germany , March 13, 2017 Future of ... ... DERMALOGs Face Matching enables to match ... characteristics forms the basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for ...
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, 2017 ... and 23andMe , the leading personal genetics company, ... Zipongo can now provide customers with personalized nutrition plans ... and biometrics, but also genetic markers impacting how their ... Zipongo,s personalized food decision support platform uses biometrics such ...
Breaking Biology News(10 mins):